Announcements Trials
Browse Landscape

Phase

Phase 2 90Phase NA 14Phase 1/2 10Phase 3 8Phase 1 6Phase 2/3 5Phase 4 2

Status

Unknown 5Completed 3Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Stomach Neoplasms 1Sarcoma 1Differentiated Thyroid Cancer 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × anlotinib × Clear all
NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Henan Cancer Hospital

Phase 2/3 Unknown
100 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02461407 2017-12-29

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
378 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
233 enrolled
Sarcoma

Sarcoma

NCT02029209 2016-12-16

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
110 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡